Repligen CORP (RGEN) Institutional Investor Snapshot (485 Funds, Q2 2026)

RGEN ranks #1216 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

485 institutions disclose a position in RGEN, but none treat it as a major bet — even Conestoga Capital Advisors, LLC, its most concentrated holder, allocates just 2.9% of its own portfolio to it.

Ameriprise Financial Inc has added to its RGEN position for two straight quarters, increasing it by $134.1M to reach $215.0M today.

Price T Rowe Associates Inc /md/ has trimmed its RGEN position for two straight quarters, cutting it by $514.5M while still holding $239.1M.

RGEN is down 3.2% today, but institutions show net buying of $1.2B this quarter — a divergence between today's price move and the underlying institutional flow.

RGEN posted net income of $41.5M over the trailing twelve months, and currently trades at a P/E of 0.2.

• Profitable — net income of $41.5M over the trailing twelve months
• Revenue grew 41.3% year over year
• Net income improved year over year, from -$13.8M to $41.5M
• Generated $117.4M in positive operating cash flow
• Current ratio of 8.37x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.40x equity — within a conventional range